To evaluate Interpersonal Treatment for Depression and Pain, a new treatment that targets the mood and interpersonal functioning of women with chronic pain.
Related Clinical Trials
Study to Evaluate the Intramuscular Depot Formulation of Aripiprazole in Patients with Schizophrenia
For patients with schizophrenia. All participants receive active medication in the double-blind study (247). Once randomized, they are eligible to participate in an open label study (248) of the Abilify long-acting depot for up to two years or when the medication is approved by the FDA.
This study is for patients with moderate to severe Crohn’s Disease who have failed or are intolerant to one or more anti-TNFα therapies. This study will test the safety and effectiveness of active study drug MEDI2070 against placebo (no study drug) which will be delivered either through intravenous (IV) method, through subcutaneous (under the skin) injections, or using both methods. After 28 weeks, patients will have the opportunity to receive open-label (active study drug) for 24 weeks.
It is hoped that this will help to reduce inflammation (swelling and irritation) within the intestines and relieve symptoms of Crohn’s disease.